Cognitive effects
Group mean performance on cognitive tests (Cogstate and HVLTR) from baseline through week 160 indicated that cognitive performance generally remained stable. There was no evidence of decline in cognition associated with long-term treatment among participants <65 years old from baseline to week 160 (Table 